Sanofi Operating Margin 2010-2024 | SNY

Current and historical operating margin for Sanofi (SNY) over the last 10 years. The current operating profit margin for Sanofi as of September 30, 2024 is 22.08%.
Sanofi Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2024-09-30 $53.03B $8.54B 16.11%
2024-06-30 $51.29B $7.84B 15.29%
2024-03-31 $50.68B $8.45B 16.67%
2023-12-31 $50.27B $9.59B 19.08%
2023-09-30 $49.01B $10.30B 21.03%
2023-06-30 $48.42B $11.11B 22.95%
2023-03-31 $48.20B $10.71B 22.21%
2022-12-31 $47.82B $10.72B 22.42%
2022-09-30 $48.72B $12.21B 25.07%
2022-03-31 $34.76B $8.80B 25.31%
2021-09-30 $35.03B $9.03B 25.79%
2021-03-31 $43.57B $10.31B 23.66%
2020-09-30 $42.75B $9.32B 21.80%
2020-03-31 $41.19B $7.94B 19.28%
2019-09-30 $41.49B $6.79B 16.37%
2019-03-31 $41.50B $6.71B 16.17%
2018-03-31 $41.43B $6.77B 16.33%
2017-12-31 $40.92B $7.07B 17.27%
2017-09-30 $40.25B $7.72B 19.19%
2017-06-30 $39.59B $8.01B 20.24%
2017-03-31 $39.14B $8.14B 20.79%
2016-12-31 $38.41B $7.59B 19.77%
2016-09-30 $39.27B $8.06B 20.52%
2016-06-30 $39.37B $7.47B 18.97%
2016-03-31 $41.16B $7.72B 18.76%
2015-09-30 $42.97B $7.96B 18.53%
2015-06-30 $43.92B $7.84B 17.84%
2014-06-30 $44.70B $8.29B 18.54%
2013-06-30 $45.22B $8.36B 18.48%
2012-06-30 $46.75B $9.00B 19.24%
2012-03-31 $47.10B $8.41B 17.86%
2011-12-31 $47.27B $8.89B 18.80%
2011-09-30 $45.65B $8.20B 17.97%
2011-06-30 $44.35B $8.97B 20.23%
2011-03-31 $42.93B $10.32B 24.03%
2010-12-31 $41.26B $9.22B 22.33%
2010-09-30 $41.28B $8.91B 21.59%
2010-06-30 $41.42B $8.83B 21.33%
2010-03-31 $41.35B $8.80B 21.28%
2009-12-31 $40.79B $8.81B 21.60%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $130.089B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $737.030B 76.34
Novo Nordisk (NVO) Denmark $472.806B 34.10
Johnson & Johnson (JNJ) United States $380.116B 15.42
AbbVie (ABBV) United States $355.549B 18.72
Merck (MRK) United States $255.130B 16.93
Novartis AG (NVS) Switzerland $218.320B 14.51
AstraZeneca (AZN) United Kingdom $197.973B 17.64
Pfizer (PFE) United States $155.049B 10.60
Innoviva (INVA) United States $1.246B 10.38